Policy Comments
The priority legislative and regulatory issues that the Cancer Policy Institute focuses on are driven by policy pillars that are centered around the values, needs, and preferences of individuals impacted by cancer. We work in conjunction with patients, patient advocacy organizations, medical associations, and other stakeholders to advance policies aimed at improving access to, affordability of, and quality of care across the cancer continuum.
CSC letter supporting the Nancy Sewell Gardner Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 2407) and urging the passage of the amended bill out of the U.S. House Committee on Ways & Means.
Group letter urging CMS to uphold the important protections under the 6PC policy as they implement the changes to the Part D program required under the IRA.
Group letter urging the Biden administration not to draft a framework for the expanded use of March-In Rights, but instead the debate about product price as a triggering event for exercise of March-In Rights should occur in Congress.
Group letter urging the Administration to finalize the HHS rules no later than April 2024, to improve coverage and care for millions of patients and people with pre-existing conditions.
Group letter commenting on the 2018 AHP Rule, supporting the Department's proposal to rescind the 2018 AHP Rule and the proposed rule's explanation of DOL's pre-2018 approach to evaluating whether an association in bona fide under ERISA.
Group letter urging the Biden Administration to address drug shortages and underscore the urgency of strengthening pharmaceutical supply chain resilience in the upcoming State of the Union address.
Group letter supporting proposal to add clarification that all prescription drugs covered by ACA plans are subject to EHB protection, as well as urges survivorship habilitative and rehabilitative services to be included as EHBs. Additionally, supports the proposal to require all market place plans to meet minimum quantitative standards for network adequacy, increasing consumer protection and representation.
Coalition letter supporting the proposal to add clarification that all prescription drugs covered by ACA health plans, including large group and self-insured plans, are subject to EHB protections.
Group letter requesting a meeting to discuss expanding FHA policy to alert homebuyers throughout the US at the time of purchase to the danger of radon in homes and the necessity of testing for radon.
Group letter urging CMS to expand access to telehealth services for Medicaid beneficiaries. Recommendations include: updating prior telehealth guidance to states to better communicate provider enrollment requirements, identify where states have authority to modernize, and provide enrollment requirements, reduce regulatory and administrative burden, and enhance Medicaid provider networks.